The estimated Net Worth of G Bradley Cole is at least $7.92 Milión dollars as of 5 June 2024. Mr Cole owns over 4,373 units of Exact Sciences stock worth over $600,997 and over the last 19 years he sold EXAS stock worth over $6,088,151. In addition, he makes $1,228,010 as Gen. Mang. of Precision Oncology at Exact Sciences.
Sign up
Mr Cole EXAS stock SEC Form 4 insiders trading
Mr has made over 102 trades of the Exact Sciences stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 4,373 units of EXAS stock worth $280,397 on 5 June 2024.
The largest trade he's ever made was exercising 60,000 units of Exact Sciences stock on 12 August 2019 worth over $1,760,400. On average, Mr trades about 4,207 units every 32 days since 2005. As of 5 June 2024 he still owns at least 9,373 units of Exact Sciences stock.
You can see the complete history of Mr Cole stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. G. Bradley Cole biography
G. Bradley Cole is the Gen. Mang. of Precision Oncology at Exact Sciences.
What is the salary of Mr Cole?
As the Gen. Mang. of Precision Oncology of Exact Sciences, the total compensation of Mr Cole at Exact Sciences is $1,228,010. There are 8 executives at Exact Sciences getting paid more, with Kevin Conroy having the highest compensation of $18,716,500.
How old is Mr Cole?
Mr Cole is 64, he's been the Gen. Mang. of Precision Oncology of Exact Sciences since . There are 7 older and 18 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.
What's Mr Cole's mailing address?
G's mailing address filed with the SEC is C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE 2 CHURCH STREET, HAMILTON, D0, HM 11.
Insiders trading at Exact Sciences
Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania a Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.
What does Exact Sciences do?
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
What does Exact Sciences's logo look like?
Complete history of Mr Cole stock trades at Exact Sciences, Kiniksa Pharmaceuticals International Plc a Castle Biosciences
Exact Sciences executives and stock owners
Exact Sciences executives and other stock owners filed with the SEC include:
-
Kevin Conroy,
Chairman of the Board, President, Chief Executive Officer -
Mark Stenhouse,
General Manager - Screening -
Jeffrey Elliott,
Chief Financial Officer -
D. Scott Coward,
Senior Vice President, Chief Administrative Officer, General Counsel, Secretary -
Jake Orville,
General Manager - Pipeline -
Ana Hooker,
Senior Vice President, Operations -
Graham Lidgard,
Senior Vice President, Chief Scientific Officer -
Kevin T. Conroy,
Chairman, Pres & CEO -
G. Bradley Cole,
Gen. Mang. of Precision Oncology -
Mark Stenhouse,
Advisor -
Graham P. Lidgard,
Emeritus Chief Science Officer -
Jeffrey T. Elliott CFA,
Exec. VP, CFO & COO -
D. Scott Coward,
Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec. -
Kathleen Sebelius,
Independent Director -
Andrew Slavitt,
Director -
Pierre Jacquet,
Independent Director -
Jake Orville,
Gen. Mang. of Pipeline -
Ana Hooker,
Sr. VP of Operations -
James Doyle,
Independent Director -
Michael Wyzga,
Independent Director -
Daniel Levangie,
Independent Director -
Katherine Zanotti,
Independent Director -
Thomas Carey,
Independent Director -
Shacey Petrovic,
Director -
Gisela Paulsen,
General Manager - Precision Oncology -
Torsten Hoof,
General Manager - International -
Freda Lewis-Hall,
Independent Director -
Scott Johnson,
Senior Vice President, Research and Development -
Vic Parker,
Head of Sales -
Tim Caprez,
Chief Compliance Counsel & VP -
Megan Jones,
Associate Mang. of Investor Relations -
Dr. Scott C. Johnson Ph.D.,
Chief Science Officer and Sr. VP of R&D -
Gary Frings,
Chief Information Officer -
Lionel Sterling,
Director -
John A. Fallon,
Director -
David Thompson,
Director -
G Bradley Cole,
General Manager - Diagnostics -
Paul J Clancy,
-
Michael J Barber,
-
Eli Casdin,
Director -
Anthony P Shuber,
Executive Vice President -
John A Jr Mccarthy,
Chief Financial Officer -
Don M Hardison,
President, CEO and Director -
Barry M Berger,
SVP, Chief Medical Officer -
William J. Megan,
SVP, Finance & PFO -
John K Bakewell,
Chief Financial Officer -
Jeffrey R Luber,
General Counsel -
Edwin M Jr Kania,
Director -
Charles R Jr Carelli,
Prin. Acct. Off. & Corp. Ctlr. -
Patrick J Zenner,
Director -
Stanley N Lapidus,
Director -
John M Krayacich,
SVP, Sales and Marketing -
Richard W Barker,
Director -
Laura S Stoltenberg,
Chief Commercial Officer -
Cornelius Iii Mcgillicudy,
Director -
Harry W Wilcox,
Senior Vice President and CFO -
Lance Willsey,
Director -
Michael E Singer,
Director -
Maneesh Arora,
Vice President -
James P Connelly,
Director -
Sally Crawford,
Director -
Sarah Condella,
EVP, Human Resources -
Timothy J Scannell,
Director -
James Herriott,
SVP, General Counsel & Sec -
Everett Cunningham,
Chief Commercial Officer -
Jacob A Orville,
EVP, GM, Screening -
Brian Baranick,
EVP, GM, Precision Oncology